4 Healthcare Stock Stories Recomended For Investment Weekend Wellness

Amgen Inc. (NASDAQ:AMGN): Closing price $105.60

After it did not obtain the clinical trial data it requested, Amgen is pressing to pay less than the $130 a share it offered earlier in August for Onyx Pharmaceuticals Inc., according to inside sources, who added that Onyx refused to give Amgen additional data on its blood-cancer treatment Kyprolis. Amgen wanted the data so as to more accurately value the drug, the sources said last week, and one indicated that Onyx does not want to give out the data in part because they pertain to individual patients. The sources also said that Amgen has not put out a new offer and is considering its next move.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

AMGN-20130823

Zimmer Holdings, Inc. (NYSE:ZMH): Closing price $80.52

On Friday, Zimmer said that it has received 510K clearance from the FDA to market the Zimmer Patient Specific Instruments Shoulder system to complement its Trabecular Metal Reverse Shoulder system for reverse shoulder arthroplasty procedures. Zimmer PSI Shoulder employs 3D visualization software to permit a surgeon to create a customized surgical plan for each patient, and then supplies patient-specific surgical instrument guides to make placement of the implant corresponding to the personalized surgical plan easier. Zimmer PSI Shoulder has been available to a limited number of surgeons in Europe since May, and it will now be made available to shoulder surgeons spanning the United States.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

ZMH-20130823

Reliv International, Inc. (NASDAQ: RELV): Closing price $2.16

Reliv announced Friday that its LunaRich tech has earned a new patent from the US Patent and Trademark Office. The composition of matter patent covers the LunaRich tech as it relates to its superior ability to deliver bioactive lunasin to the body. Lunasin is a naturally occurring peptide that scientists have identified as the key to many of the documented health benefits of soy. Reliv is a maker of nutritional supplements that promote optimal health.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

RELV-20130823

GlaxoSmithKline (NYSE:GSK): Closing price $52.19

Glaxo reported Friday that the first of its four Phase III studies, the SHIELD-1 study, which is investigating vercirnon, an inhibitor of the chemokine receptor known as CCR9, in patients with moderate-to-severe Crohn’s disease failed to meet the primary endpoint of improvement in clinical response and the key secondary endpoint of clinical remission. The rates of serious adverse events and withdrawals due to adverse events were found to be similar among all treatment groups including the placebo group, with a trend in dose-dependent increases in overall adverse event rates. GSK has said that it will continue to examine the safety and efficacy results to inform decisions about the clinical development program for vercirnon. New recruitment and dosing in the ongoing clinical program are stopped pending further review of the SHIELD-1 results.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

GSK-20130823

Don’t Miss: Ted Cruz: Watch Out America, Obamacare Could Be Addicting.